Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582141 | 0.89 | NQO2 (0.41) | PTK2NQO2EGFR | |
| SCHEMBL5582011 | 0.87 | PTK2 (0.47) | PTK2EGFR | |
| SCHEMBL5581980 | 0.87 | NQO2 (0.36) | NQO2EGFRBRAF | |
| SCHEMBL5581933 | 0.83 | CCR4 (0.33) | NQO2EGFR | |
| SCHEMBL5581881 | 0.83 | KMO (0.37) | PDGFRBPDGFRANQO2EGFRCLK1 | |
| SCHEMBL5581955 | 0.83 | CYP17A1 (0.31) | PTK2NQO2EGFR | |
| SCHEMBL5582085 | 0.82 | CSNK2A2 (0.38) | NQO2EGFR | |
| SCHEMBL5581776 | 0.82 | FYN (0.39) | PDGFRBPDGFRANQO2EGFRDYRK1A | |
| SCHEMBL5582117 | 0.81 | PTK2 (0.45) | PTK2NQO2EGFR | |
| SCHEMBL5585115 | 0.80 | PIK3CD (0.39) | NQO2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | PTK2 4482/4885PDGFRB 2343/4885PDGFRA 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.